323990.Kq
The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.
Business. The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.
The company maintains a strong liquidity position, with a current ratio of 8.53, indicating a significant ability to meet short-term obligations. The price-to-book ratio of 2.34 suggests that the market values the company at a premium relative to its book value. However, the company's negative operating income of -16,497,506,500 KRW and net income of -13,340,022,550 KRW indicate a lack of profitability.
The company's return on equity of -21.82% and return on assets of -19.94% are significantly below the industry norms, highlighting a poor performance in generating returns from equity and assets. The debt-to-equity ratio of 0.03 suggests a conservative capital structure with minimal leverage.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic diversification mentioned in the available data. This concentration may pose a risk if the segment faces challenges or market downturns.
The company's growth trajectory is uncertain, with no specific numeric deltas provided in the outlook for the current or next fiscal year. The negative operating and free cash flows of -10,627,367,070 KRW and -17,928,264,300 KRW, respectively, suggest ongoing financial strain.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is stable, with a low debt-to-equity ratio and substantial cash and equivalents of 6,222,452,590 KRW. No dilution potential is noted in the basic shares outstanding, which remain unchanged at 23,173,887.
Recent events, as reflected in the financial snapshot, show a significant negative operating income and net loss, indicating ongoing financial challenges. No specific recent filings or transcripts are detailed in the available data.
- The company has a strong liquidity position with a high current ratio of 8.53.
- The company is not profitable, with a negative operating income and net income.
- The company's return on equity and return on assets are significantly below industry norms.
- The company has a conservative capital structure with a low debt-to-equity ratio.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided in the outlook.
- The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 323990.KQ Market data — financials · 2026-05-26